# US 8,278,284 B2 · Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,284 B2
- Document ID: US8278284B2
- Status: Granted
- Kind: B2
- Application number: 11/884,738
- Filed: 2006-02-21
- Published: 2009-09-17
- Granted: 2012-10-02
- Earliest claimed: 2005-02-23
- Inventors: Masanori Miyazaki; Yoshikazu Yonemitsu; Yasuhiro Ikeda; Katsuo Sueishi; Toshiaki Tabata; Akihiro Iida; Yasuji Ueda; Mamoru Hasegawa
- Web page: https://patentgrep.com/patent/US8278284B2

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/475: Growth factors; Growth regulators
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/15045: Special targeting system for viral vectors
- C12N 2810/6081: rhabdoviridae, e.g. VSV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides novel methods for treating diseases associated with apoptotic degeneration in ocular tissue cells by effective administration of pigment epithelium derived factor (PEDF). The present inventors studied PEDF as a means to prevent ganglion cell death, the final pathology of glaucoma. The present invention is particularly focused on SIV vectors for effective methods for delivering PEDF, and constructed an SIV-PEDF vector. When the SIV-PEDF vector was administered subretinally to an ischemia reperfusion model and NMDA-induced model, a significant suppression effect on ganglion cell death was observed. The present inventors therefore discovered that the SIV-PEDF vector is an effective pharmaceutical agent for treating diseases associated with apoptotic degeneration in ocular tissue cells, such as glaucoma.

## Claims

### Claim 1

A pharmaceutical agent for treating a disease associated with apoptotic degeneration in ocular tissue cells, which comprises a recombinant simian immunodeficiency virus vector encoding a pigment epithelium derived factor (PEDF), and a pharmaceutically acceptable vehicle, wherein said vector is encoded by the nucleotide sequence of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The pharmaceutical agent of claim 1, wherein the simian immunodeficiency virus vector is pseudotyped with VSV-G.

### Claim 3 (depends on 1)

The pharmaceutical agent of claim 1, wherein the disease associated with apoptotic degeneration in ocular tissue cells is any one of glaucoma, retinitis pigmentosa, retinal detachment, and retinal ischemic disease.

### Claim 4 (depends on 1)

A method for producing the pharmaceutical agent of claim 1, said method comprising:
obtaining a recombinant simian immunodeficiency virus vector which is encoded by the nucleotide sequence of SEQ ID NO: 2, and
adding a pharmaceutically acceptable vehicle to said vector to produce the pharmaceutical agent.

### Claim 5 (depends on 4)

The method of claim 4, wherein the recombinant simian immunodeficiency virus vector is produced by introducing a vector comprising the nucleotide sequence of SEQ ID NO: 2 into a packaging cell line into which a packaging vector comprising the nucleotide sequence of SEQ ID NO: 3 has been introduced.

### Claim 6

A vector encoding a simian immunodeficiency virus genomic RNA, which comprises the nucleotide sequence of SEQ ID NO: 2.

### Claim 7 (depends on 6)

A simian immunodeficiency virus genomic RNA encoded by the vector of claim 6.
